Hernandez Elliot, Dominguez David, Medina-Rioja Raul, Martínez-Angeles Victoria, López-Hernández Juan Carlos
Emergency Department, Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suárez, Mexico City, MEX.
Neurology Department, Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suárez, Mexico City, MEX.
Cureus. 2024 Jul 23;16(7):e65201. doi: 10.7759/cureus.65201. eCollection 2024 Jul.
We present the case of a 60-year-old male patient with Guillain-Barré syndrome (GBS) who experienced treatment-related fluctuations (TRF) with a history of ayahuasca consumption. The patient presented to the neurological emergency department without a history of infection (upper respiratory tract or diarrhea) or vaccination in the past four weeks, but 14 days prior, the patient had consumed ayahuasca. Upon admission, the patient exhibited progressive weakness in all four limbs, with no cranial nerve involvement, a muscle strength Medical Research Council (MRC) score of 36/60, and generalized areflexia. Cerebrospinal fluid analysis showed slightly elevated protein levels at 50 mg/dL and a cell count of 2 (lumbar puncture was performed three days after the onset of symptoms). Neurophysiological studies met the criteria for the acute motor-sensory axonal neuropathy (AMSAN) variant. A diagnosis of GBS was established, Brighton criteria grade 1. The patient received treatment with intravenous human immunoglobulin, resulting in improvement with an MRC score of 48/60 at discharge. However, on day 10, he returned with worsening muscle strength (MRC score of 20/60), necessitating ventilatory support. TRF was considered, and retreatment with human immunoglobulin was initiated.
我们报告一例60岁男性格林-巴利综合征(GBS)患者,其有使用死藤水的病史,并出现了与治疗相关的病情波动(TRF)。该患者前往神经科急诊就诊,过去四周无感染史(上呼吸道感染或腹泻)或疫苗接种史,但在就诊前14天,患者曾使用过死藤水。入院时,患者四肢渐进性无力,无颅神经受累,医学研究委员会(MRC)肌力评分为36/60,且全身腱反射消失。脑脊液分析显示蛋白水平略有升高,为50mg/dL,细胞计数为2(症状出现三天后进行腰椎穿刺)。神经生理学研究符合急性运动感觉轴索性神经病(AMSAN)变异型的标准。确诊为GBS,布莱顿标准1级。患者接受了静脉注射人免疫球蛋白治疗,出院时MRC评分为48/60,病情有所改善。然而,在第10天,他因肌力恶化(MRC评分为20/60)再次就诊,需要呼吸机支持。考虑为TRF,遂开始再次使用人免疫球蛋白治疗。